Viewing nowDongkwang Pregabalin Capsule 150 mg
Pregabalin 150mg
Hard capsule · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 201112306 · Notified 2011.12.29 · Insurance code 645905340
Neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia
This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, whether they have secondary generalized symptoms or not. Additionally, it is effective in the treatment of fibromyalgia. It is used to improve symptoms related to various nervous system disorders.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. This medicine is primarily excreted by the kidneys, so the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If needed, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140-age(years)] × body weight (kg)/72 × serum creatinine concentration (serum creatinine, mg/dL) *: For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior; therefore, if changes in mood or unusual behavior occur during treatment, it is crucial to inform a healthcare professional immediately. Patients with allergies to any ingredients in this medicine or certain genetic lactose metabolism disorders should not take it. Diabetic patients should be cautious as weight gain may require dose adjustment of blood sugar control medications. If allergic reactions such as angioedema occur, discontinue use of the medication immediately. Elderly patients need to be cautious due to higher risk of accidents from dizziness or drowsiness. This medication may cause blurred vision or vision changes; consult a healthcare professional if such symptoms appear. Discontinuing this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be tapered off under a physician's guidance. Patients with a history of drug abuse may have an increased risk of misuse with this medication and should be managed carefully. Patients with impaired renal function may require dose adjustments. Patients with heart disease may be at risk for congestive heart failure and should be monitored closely. There may be an increased risk of respiratory depression if taken in combination with central nervous system depressants. During early pregnancy, there may be a risk of fetal malformations, so women who are pregnant or planning to become pregnant must consult with a healthcare professional and use effective contraception. Breastfeeding women should consult a healthcare professional about whether to stop breastfeeding or discontinue the medication since it can be passed through breast milk. It is advisable to avoid dangerous activities such as driving or operating machinery while experiencing dizziness or drowsiness after taking this medication. In case of overdose, symptoms such as confusion, drowsiness, or depression may occur, and immediate medical attention should be sought. Keep out of reach of children and store in a safe place; transferring to another container may pose risks of accidents or degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored tightly closed in an airtight container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 15 and 30 degrees Celsius.
Capsule with white upper part and white lower part containing a white to pale yellow powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.